• Avalo Therapeutics posted a net loss of $19.6 million for the quarter ended March 31, 2026, widening from a $13.1 million loss a year earlier.
• Cash used in operating activities increased to $17.7 million from $9.5 million in the prior-year quarter.
• Research and development expense climbed to $14.05 million from $9.12 million, driven by higher clinical and CMC spending tied to abdakibart trial activity and preparations for pivotal studies.
• General and administrative costs rose to $6.85 million from $5.55 million, reflecting higher salaries and stock-based compensation.
• Cash, cash equivalents and short-term investments totaled $82 million as of March 31, 2026; May 7 follow-on offering generated gross proceeds of about $431.3 million, with net proceeds expected to be about $405 million, as abdakibart Phase 2 LOTUS trial in hidradenitis suppurativa met its primary endpoint and a registrational Phase 3 program is planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001534120-26-000033), on May 13, 2026, and is solely responsible for the information contained therein.